Omeros Corporation Reports Improved Net Loss of $25.4 Million in Q2 2025

Omeros Corporation reported a net loss of $25.4 million for the second quarter of 2025, a significant improvement compared to a net loss of $56.0 million in the same period of 2024. For the six months ended June 30, 2025, the company recorded a net loss of $58.9 million, down from $93.2 million in the prior year. Total revenues for the second quarter were $1.2 million, primarily from royalties related to the OMIDRIA contract, while total expenses decreased to $32.4 million from $59.2 million year-over-year, driven by reduced research and development costs.

The company’s financial position showed a decline in total assets, which fell to $200.6 million as of June 30, 2025, from $277.1 million at the end of 2024. Current assets decreased significantly, primarily due to a reduction in cash and cash equivalents, which dropped to $1.9 million from $3.4 million. Omeros also reported a total shareholders' deficit of $228.7 million, compared to $182.6 million at the end of the previous fiscal year, reflecting ongoing operational losses.

Strategically, Omeros has made notable advancements in its clinical programs. The company resubmitted its Biologics License Application (BLA) for narsoplimab to the FDA for the treatment of thrombotic microangiopathy, with a new target action date set for December 26, 2025. Additionally, Omeros submitted a Marketing Authorization Application (MAA) for narsoplimab in the European Union, which is currently under review. The company has also paused its Phase 3 clinical development program for zaltenibart to prioritize capital allocation towards narsoplimab and other key programs.

Operationally, Omeros has seen a decrease in research and development expenses, which totaled $22.0 million for the second quarter, down from $45.3 million in the prior year. This reduction is attributed to lower manufacturing costs and the winding down of certain clinical trials. The company’s cash used in operations for the first half of 2025 was $57.8 million, a decrease from $87.8 million in the same period of 2024. As of June 30, 2025, Omeros had cash, cash equivalents, and short-term investments totaling $28.7 million, which is critical for funding ongoing operations and meeting debt obligations.

Looking ahead, Omeros acknowledges the need for additional capital to support its business plan, as it currently lacks a sufficient revenue stream to cover operating costs. The company is exploring various financing options, including public and private equity offerings, additional debt transactions, and potential asset sales or licensing agreements. The management has expressed that the ability to continue as a going concern will depend on generating positive cash flow, securing additional financing, and potentially entering strategic alliances.